) recently announced that ViiV Healthcare's HIV drug, Tivicay,
has been cleared by the U.S. Food and Drug Administration (FDA).
The FDA approved Tivicay as an add-on therapy to other
antiretroviral agents for the treatment of patients suffering
from HIV-1, who are above 12 years and weigh at least 88 lbs (40
GILEAD SCIENCES (GILD): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
We note that ViiV Healthcare, a company focused on the treatment
of HIV, was established by Glaxo and
) in 2009. After certain amendments in Oct 2012, Glaxo, Pfizer
and Shionogi now own 76.5%, 13.5% and 10% of ViiV Healthcare,
The FDA approved Tivicay on the basis of encouraging data from
four pivotal phase III trials (n ~ 2,557). Tivicay is an
integrase inhibitor. ViiV Healthcare is also looking to get the
HIV drug approved in the EU and has submitted a marketing
authorisation application to the European Medicines Agency for
the same in Dec 2012.
A fixed dose combination of Tivicay and abacavir/lamivudine is
also being evaluated. ViiV Healthcare expects to submit
regulatory applications for the drug later in the year.
We note that sales at ViiV Healthcare have been on the decline
over the past few quarters due to generic erosion of Combivir,
Epivir and other several products in the U.S. Tivicay, with
multi-million dollar potential, should help the top line rebound.
Currently prescribed therapies for HIV include
Johnson and Johnson
) Intelence and
Gilead Sciences Inc.
) Stribild and Complera.
Glaxo currently holds a Zacks Rank #3 (Hold). Currently, stocks
such as Gilead Sciences look more attractive in the pharma space
with a Zacks Rank #1 (Strong Buy).